PATIENT EXPERIENCE ASSESSMENTS IN ADVANCED GASTRIC, ESOPHAGEAL, AND GASTROESOPHAGEAL JUNCTION CANCER STUDIES
Author(s)
Morlock R1, Turnbull J2, Rhode T2, Hawryluk E2, Gwaltney C2, Paty J2, Holmstrom S3
1Astellas Pharma Global Development, Inc., Northbrook, IL, USA, 2QuintilesIMS Consulting Services, New York, NY, USA, 3Astellas Pharma Europe, B.V., Leiden, The Netherlands
OBJECTIVES: The objectives of this research were to identify signs, symptoms, and impacts of advanced gastric, esophageal, and gastroesophageal junction cancers (GC/EC/GEJC) and map these to the patient-reported outcomes (PRO) instruments frequently used to assess patient experience. METHODS: A structured, targeted literature and clinical trial search of HRQoL and PRO studies in English for GC/EC/GEJC from was conducted. Results were supplemented with patient blogs and message-boards discovered through an internet search to identify and corroborate the symptoms and impacts. A preliminary conceptual model was developed, summarizing the signs, symptoms, and impacts frequently mentioned by the existing literature or patient websites. RESULTS: CONCLUSIONS: In patients with advanced GC/EC/GEJC, the most important symptoms and impacts were disease-specific (e.g., dysphagia) and general (e.g., satiety), indicating that a general instrument supplemented by a disease-specific module can best represent patient experience. The QLQ-C30 and OG25 used together comprehensively assess the most important patient symptoms and impacts. The OG25 is validated to measure concepts in both GC/EC/GEJC, and covers more concepts. Further research through patient concept elicitation interviews is warranted to elucidate priority symptoms of advanced GC/EC/GEJC, based on frequency and disturbance to patients.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN222
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology